By Marie Rosenthal
Ticagrelor (Brilinta, AstraZeneca) without aspirin, showed benefit in different types of patients with cardiovascular (CV) disease, according to research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology.
Results from two subgroup analyses of the phase 4 TWILIGHT trial showed ticagrelor monotherapy reduced the risk for clinically relevant bleeding over 12 months compared with dual antiplatelet therapy